Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer

Thumbnail
View/ Open

Show full item record
Author
Bulumulle, Anushi; Brody, Heather; Macherla, Shravanti; Walker, Paul R.; Sehgal, Kartik; Gill, Ritu R.; Qilleri, Aleksandra; McDonald, Danielle C.; Cherry, Cynthia R.; Shea, Meghan; Huberman, Mark S.; VanderLaan, Paul A.; Weiss, Glen J.; Costa, Daniel B.; Rangachari, Deepa
URI
http://hdl.handle.net/10342/11327
Subject
 Extended-interval dosing; Immune-related adverse event; Patient-physician preference 
Date
2021
Citation:
APA:
Bulumulle, Anushi, & Brody, Heather, & Macherla, Shravanti, & Walker, Paul R., & Sehgal, Kartik, & Gill, Ritu R., & Qilleri, Aleksandra, & McDonald, Danielle C., & Cherry, Cynthia R., & Shea, Meghan, & Huberman, Mark S., & VanderLaan, Paul A., & Weiss, Glen J., & Costa, Daniel B., & Rangachari, Deepa. (January 2021). Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer. , (), - . Retrieved from http://hdl.handle.net/10342/11327

Display/Hide MLA, Chicago and APA citation formats.

MLA:
Bulumulle, Anushi, and Brody, Heather, and Macherla, Shravanti, and Walker, Paul R., and Sehgal, Kartik, and Gill, Ritu R., and Qilleri, Aleksandra, and McDonald, Danielle C., and Cherry, Cynthia R., and Shea, Meghan, and Huberman, Mark S., and VanderLaan, Paul A., and Weiss, Glen J., and Costa, Daniel B., and Rangachari, Deepa. "Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer". . . (), January 2021. September 26, 2023. http://hdl.handle.net/10342/11327.
Chicago:
Bulumulle, Anushi and Brody, Heather and Macherla, Shravanti and Walker, Paul R. and Sehgal, Kartik and Gill, Ritu R. and Qilleri, Aleksandra and McDonald, Danielle C. and Cherry, Cynthia R. and Shea, Meghan and Huberman, Mark S. and VanderLaan, Paul A. and Weiss, Glen J. and Costa, Daniel B. and Rangachari, Deepa, "Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer," , no. (January 2021), http://hdl.handle.net/10342/11327 (accessed September 26, 2023).
AMA:
Bulumulle, Anushi, Brody, Heather, Macherla, Shravanti, Walker, Paul R., Sehgal, Kartik, Gill, Ritu R., Qilleri, Aleksandra, McDonald, Danielle C., Cherry, Cynthia R., Shea, Meghan, Huberman, Mark S., VanderLaan, Paul A., Weiss, Glen J., Costa, Daniel B., Rangachari, Deepa. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Nonesmall-cell Lung Cancer. . January 2021; (): . http://hdl.handle.net/10342/11327. Accessed September 26, 2023.
Collections